secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001104659-25-043534
Event type: regulatory
Sentiment:  negative
Materiality: 0.78
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents receives FDA denial for DrugSorb-ATR De Novo; plans appeal if unresolved
--------------------------------------------------------------------------------

- FDA issued denial letter on April 25, 2025 for DrugSorb-ATR De Novo Request, citing remaining deficiencies.
- DrugSorb-ATR is a Breakthrough Device to reduce bleeding in CABG surgery patients on Brilinta.
- CytoSorbents has met with FDA and will continue discussions; formal appeal due within 60 days if unresolved.
- CEO expects final regulatory decision still in 2025 despite the denial.
- No therapies currently approved in U.S. for this indication; tens of thousands of patients at risk annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925043534/0001104659-25-043534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925043534/tm2511160d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-043534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer